Computational Chemistry

Covalent modifiers are crucial to the development of new drugs. Approximately 30% of all marketed drugs act as covalent inhibitors today. Despite the initial concerns about potential off-target toxicity, covalent inhibitors offer numerous advantages. In this way, there is continuous research, especially on cancer targets.

Highly sensitive methods for hit detection in FBDD are an absolute must. FBDD applies various biochemical, biophysical, and computational techniques to efficiently identify the event of weak fragment binding to a specific protein target. Life Chemicals offers a proprietary collection of Fragment Libraries to support these drug discovery efforts.

Metalloenzyme inhibitors form one of the most promising medication classes used to treat various pathologies, including cancer, viral and bacterial infections, neurodegenerative and other diseases. Life Chemicals is offering several screening compound libraries of small organic molecules that serve as potential chelating ligands.

Epigenetics is an exciting research field with vast clinical implications. At Life Chemicals, we have recently updated and re-designed our Epigenetic Targeted and Focused Libraries with an emphasis on most-promising epigenetic-related targets and ligands in response to epigenetic drug discovery trends.

Rare Disease Day is celebrated annually on the last day of February. Willing to assist in further findings related to drug discovery for rare diseases, Life Chemicals offers the extensive set of targeted libraries: Anti-inflammatory Library, Protease Targeted Library, Ion Channel Screening Libraries and many more.